» Articles » PMID: 29746413

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY: A Pilot Study

Overview
Journal Retina
Date 2018 May 11
PMID 29746413
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate, in eyes with radiation maculopathy, the effect of 2-month-interval anti-vascular endothelial growth factor therapy on best-corrected visual acuity and foveal avascular zone (FAZ) enlargement using optical coherence tomography angiography.

Methods: Consecutive treatment-naive patients with radiation maculopathy after proton beam irradiation for choroidal melanoma were retrospectively included. Clinical and optical coherence tomography angiography data at baseline and the 6-month visit were recorded. Two independent observers measured FAZ area manually on 3 × 3-mm optical coherence tomography angiography images of the superficial capillary plexus and deep capillary plexus. Patients were encouraged to follow strictly a 2-month-interval intravitreal anti-vascular endothelial growth factor treatment by either bevacizumab or ranibizumab. Findings were analyzed based on the adherence to the treatment scheme.

Results: According to the adherence to the bimonthly anti-vascular endothelial growth factor treatment protocol, patients were categorized into 3 groups: treatment protocol (n = 19, strict adherence), variable intervals (n = 11, intervals other than 2 months), and no treatment (n = 11). The estimated radiation dose to the foveola in each group was 49 ± 16, 46 ± 17, and 46 ± 18 cobalt gray equivalent, respectively (P = 0.85). For the entire cohort, best-corrected visual acuity loss (P < 0.02) and FAZ enlargement (P < 0.0001) were observed over 6 months. Best-corrected visual acuity loss was significantly less pronounced in the treatment-protocol group than in the variable-interval and no-treatment groups (P = 0.007 and P = 0.004). The FAZ enlargement was lower in the treatment-protocol group compared with the variable-interval group for both superficial capillary plexus (P = 0.029) and deep capillary plexus (P = 0.03), and to the no-treatment group for the deep capillary plexus only (P = 0.016).

Conclusion: Decrease in best-corrected visual acuity and FAZ enlargement on optical coherence tomography angiography occurred over 6 months in eyes with radiation maculopathy and were significantly reduced under 2-month-interval anti-vascular endothelial growth factor therapy.

Citing Articles

Association between Obstetric Complications and Intravitreal Anti-Vascular Endothelial Growth Factor Agents or Intravitreal Corticosteroids.

Ben Ghezala I, Mariet A, Benzenine E, Bardou M, Bron A, Gabrielle P J Pers Med. 2022; 12(9).

PMID: 36143159 PMC: 9501719. DOI: 10.3390/jpm12091374.


Reduced blood flow by laser speckle flowgraphy after I-plaque brachytherapy for uveal melanoma.

Tamplin M, Wang J, Vitale A, Hashimoto R, Garvin M, Binkley E BMC Ophthalmol. 2022; 22(1):285.

PMID: 35765019 PMC: 9238054. DOI: 10.1186/s12886-022-02505-9.


Longitudinal optical coherence tomography angiography (OCT-A) in a patient with radiation retinopathy following plaque brachytherapy for uveal melanoma.

Binkley E, Tamplin M, Vitale A, Boldt H, Kardon R, Grumbach I Am J Ophthalmol Case Rep. 2022; 26:101508.

PMID: 35392251 PMC: 8980489. DOI: 10.1016/j.ajoc.2022.101508.


Temporal Relationship Between Visual Field, Retinal and Microvascular Pathology Following 125I-Plaque Brachytherapy for Uveal Melanoma.

Tamplin M, Deng W, Garvin M, Binkley E, Hyer D, Buatti J Invest Ophthalmol Vis Sci. 2021; 62(1):3.

PMID: 33393969 PMC: 7794259. DOI: 10.1167/iovs.62.1.3.


Chorioretinal Side Effects of Therapeutic Ocular Irradiation: A Multimodal Imaging Approach.

Midena G, Parrozzani R, Frizziero L, Midena E J Clin Med. 2020; 9(11).

PMID: 33138120 PMC: 7693915. DOI: 10.3390/jcm9113496.